Abstract:Inflammation is associated with a variety of diseases. The hallmark of inflammation is leukocyte infiltration at disease sites in response to pathogen- or damage-associated chemotactic molecular patterns (PAMPs and MAMPs), which are recognized by a superfamily of seven transmembrane, Gi-protein-coupled receptors (GPCRs) on cell surface. Chemotactic GPCRs are composed of two major subfamilies: the classical GPCRs and chemokine GPCRs. Formyl-peptide receptors (FPRs) belong to the classical chemotactic GPCR subfamily with unique properties that are increasingly appreciated for their expression on diverse host cell types and the capacity to interact with a plethora of chemotactic PAMPs and MAMPs. Three FPRs have been identified in human: FPR1-FPR3, with putative corresponding mouse counterparts. FPR expression was initially described in myeloid cells but subsequently in many non-hematopoietic cells including cancer cells. Accumulating evidence demonstrates that FPRs possess multiple functions in addition to controlling inflammation, and participate in the processes of many pathophysiologic conditions. They are not only critical mediators of myeloid cell trafficking, but are also implicated in tissue repair, angiogenesis and protection against inflammation-associated tumorigenesis. A series recent discoveries have greatly expanded the scope of FPRs in host defense which uncovered the essential participation of FPRs in step-wise trafficking of myeloid cells including neutrophils and dendritic cells (DCs) in host responses to bacterial infection, tissue injury and wound healing. Also of great interest is the FPRs are exploited by malignant cancer cells for their growth, invasion and metastasis. In this article, we review the current understanding of FPRs concerning their expression in a vast array of cell types, their involvement in guiding leukocyte trafficking in pathophysiological conditions, and their capacity to promote the differentiation of immune cells, their participation in tumor-associated inflammation and cancer progression. The close association of FPRs with human diseases and cancer indicates their potential as targets for the development of therapeutics.

Structure and Drug Development of the Human Formylpeptide Receptors FPR1 and FPR2.

Molecular recognition of formylpeptides and diverse agonists by the formylpeptide receptors FPR1 and FPR2

Structure of Formylpeptide Receptor 2-Gi Complex Reveals Insights into Ligand Recognition and Signaling

Structural basis for recognition of N-formyl peptides as pathogen-associated molecular patterns

Novel Small‐molecule Agonists of Human Formyl Peptide Receptors and Pharmacophore Models of their Recognition

International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family

Formylpeptide receptor 2: Nomenclature, structure, signalling and translational perspectives: IUPHAR review 35

Molecular Biology for Formyl Peptide Receptors in Human Diseases

Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1

Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses

Receptors for chemotactic formyl peptides as pharmacological targets

Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation.

Comparative analysis of Formyl peptide receptor 1 and Formyl peptide receptor 2 reveals shared and preserved signaling profiles

Regulation of inflammation by members of the formyl-peptide receptor family

Strategies for positioning fluorescent probes and crosslinkers on formyl peptide ligands

Mol081315 389..398

Structural Basis for Ligand Recognition and Activation of the Prostanoid Receptors

Functional Characterization of Three Mouse Formyl Peptide Receptors.

Development of potent antagonists for formyl peptide receptor 1 based on Boc-Phe-D-Leu-Phe-D-Leu-Phe-OH

New Development In Studies Of Formyl-Peptide Receptors: Critical Roles In Host Defense

The ligand binding site of the formyl peptide receptor maps in the transmembrane region